Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) unit Chengdu Shengdi Pharmaceutical obtained the approval of China's drug regulator to begin clinical trials for its HRS-3095 tablets.
The drug is being developed to treat primary immune thrombocytopenia and autoimmune hemolytic anemia, according to a Thursday aftermarket filing with the Shanghai Stock Exchange.